No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., along with its affiliated entities, is dedicated to the research, development, production, and commercialization of biopharmaceutical products. The company leverages its genetic engineering platform to advance antibody-drug conjugates (ADCs), including CD30-DM1 ADC and Trop2-SN38 ADC, both in Phase I clinical trials for various tumors. Trop2-BB05 ADC is undergoing preclinical evaluation for lung and triple-negative breast cancers, while HER2 ADC has completed preclinical studies for metastatic breast and gastric cancers. Furthermore, Fudan-Zhangjiang utilizes its photodynamic technology platform, featuring hemoporfin in Phase IV clinical trials for port-wine stains, and aminolevulinic acid, which is progressing through Phase II trials for HPV-related cervical conditions and acne, having also finished preclinical investigation for brain gliomas. Its nanotechnology platform is advancing drugs like Nanoparticle Albumin-bound Paclitaxel, undergoing preclinical assessment for oncological applications, and Doxorubicin liposome, also under development for tumors. The firm's expertise in oral solid preparations encompasses obeticholic acid for hepatobiliary and autoimmune disorders; timolol maleate cream, currently in preclinical studies for infantile hemangioma; and the oral formulation FZJ-003, which is in Phase I clinical trials for rheumatoid arthritis and Phase II for atopic dermatitis and ulcerative colitis. Beyond pharmaceuticals, the company is involved in developing both pharmaceutical and medical devices, as well as medical diagnostic solutions and associated services. It also markets everyday consumer goods, clinical laboratory analysis equipment, and relevant software. Additional activities include technology innovation, licensing, consultancy, and promotional efforts, alongside the manufacturing of lyophilized powder injections and active pharmaceutical ingredients (APIs). The company also allocates capital to international medical ventures. Established in 1996, the company operates from its headquarters in Shanghai, People's Republic of China.
www.fd-zj.comNo one on the platform currently holds 1349.HK.
No tracked institution reports a position in 1349.HK as of their last filing.
No one on the platform has traded 1349.HK yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | -3.3% | -3.8% | ||||
| Profit Margin % | -22.4% | 5.6% | 12.8% | |||
| Free Cash Flow Margin % | 16.1% | 5.0% | 8.6% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $691M | +0.0% | $0.17 | $0.17–$0.17 | — | 1 |
| 2027 | $726M | +5.1% | $0.12 | $0.12–$0.12 | — | 1 |
| 2028 | $912M | +25.6% | $0.20 | $0.20–$0.20 | — | 1 |
| 2029 | $668M | -26.8% | $0.24 | $0.24–$0.24 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 1349.HKShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. | $2.50 | +0.20% | $850M | — |
| 0239.HKPak Fah Yeow International Limited | $2.48 | +1.02% | $773M | — |
| 0383.HKTian An Medicare Limited | $0.78 | -0.64% | $785M | — |
| 0950.HKLee's Pharmaceutical Holdings Limited | $1.13 | -1.74% | $665M | — |
| 1846.HKEuroEyes International Eye Clinic Limited |
| $2.30 |
| +0.00% |
| $735M |
| — |
| 2257.HKSirnaomics Ltd. | $3.88 | -1.15% | $423M | — |
| 2500.HKVenus Medtech (Hangzhou) Inc. | $1.16 | +5.00% | $509M | — |
Source: Financial Modeling Prep · peers by sector/industry